Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related death in industrialized countries. Even if the healing chances are very high after definitive treatment of localized disease, 20-30% of patients experience recurrence.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
A review of the literature on the management of local recurrent prostate cancer was conducted using the Medline and Embase electronic databases. Search terms included biochemical relapse, PSA recurrence, prostate cancer, prostate cancer recurrence, prostate salvage therapy, radiorecurrent prostate cancer, Re-HIFU, post HIFU, post cryoablation, postradiation, and postprostatectomy salvage. The search was restricted to English-language articles. The websites of guidelines organizations (EAU, AUA, NICE) were consulted in order to identify evidence-based practice guidelines. The present role of salvage prostatectomy and radiation therapy was studied and today's outcomes and tomorrow perspectives of salvage focal therapies as cryoablation and HIFU have been analyzed.
Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2015 Sep 09 [Epub ahead of print]
G Palermo, N Foschi, D D'Agostino, E Sacco, P Bassi, F Pinto
Catholic University Of Sacred Heart, Urology Department, A. Gemelli University Hospital, Rome, Italy